文献速递乳腺癌放疗

乳腺癌可豁免放疗患者的分子风险分层决策

Molecular Risk Stratification for Decision-Making Among Patients With Breast Cancer Eligible to Omit Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-03-25

该研究基于机构前瞻性数据库,评估≥65岁早期雌激素受体阳性乳腺癌保乳术后患者,按Oncotype DX复发评分(RS≤25 vs >25)分层。结论认为RS未能在里程碑豁免放疗试验之外进一步细化复发风险。

要点

  • ≥65岁早期ER阳性乳腺癌保乳术后,RS≤25与>25组局部复发无显著差异。
  • 未放疗患者中RS>25组局部复发率数值较高但无统计学差异。
  • Oncotype DX RS未能在已有豁免放疗试验之外进一步分层复发风险。

核心结论

  • 在≥65岁早期雌激素受体阳性乳腺癌保乳术后患者中,Oncotype DX复发评分未能在里程碑豁免放疗试验之外进一步细化局部复发风险以辅助放疗决策。
  • 尽管未放疗且RS>25的患者数量有限,该亚组局部复发风险未显著高于低分子风险组,提示风险评分不必成为放弃辅助放疗的绝对排除标准。

研究设计与样本

  • 基于前瞻性维护的机构数据库,纳入≥65岁接受保乳手术的早期雌激素受体阳性乳腺癌患者(即推定符合豁免放疗条件者)。
  • 按临床病理特征及Oncotype DX复发评分(≤25 vs >25)分层,评估放疗接受情况与肿瘤学结局及生存。
  • 总队列1587例,RS≤25者1455例(92%),RS>25者132例(8%);中位随访74.4个月。

关键数值与推荐

  • Oncotype DX复发评分分层阈值:≤25 vs >25。

临床怎么用

  • 对于≥65岁早期雌激素受体阳性乳腺癌保乳术后考虑豁免放疗的患者,Oncotype DX复发评分不宜单独用于 disqualify 放疗豁免决策。
  • RS>25且选择豁免放疗的患者局部复发风险在本文中未显著升高,但该亚组样本量有限,需结合其他因素个体化评估。

局限性

  • 未放疗且RS>25的患者数量有限(n=19),该亚组分析统计效能不足。
  • 本文为基于机构数据库的回顾性分析,需更大样本的前瞻性研究进一步阐明分子检测在放疗决策中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation therapy (RT) following breast-conserving surgery reduces the risk of recurrence for early-stage breast cancer. A subset of patients with favorable clinical and pathologic characteristics can safely omit RT with a modest increase in recurrences, yet without survival implications. We sought to evaluate whether molecular risk profiling among such patients could further stratify them into (1) a higher-risk subgroup that may be inappropriate for RT omission and (2) an exceedingly favorable subgroup that might more strongly consider RT omission. METHODS AND MATERIALS: Using a prospectively maintained institutional database, we evaluated patients aged ≥65 years who underwent breast-conserving surgery for early-stage, estrogen receptor-positive breast cancer (ie, patients putatively eligible for RT omission). Patients were stratified by clinicopathologic features and Oncotype DX Recurrence Score (RS; ≤25 vs >25) and were evaluated for oncologic outcomes and survival by receipt of RT. RESULTS: The overall cohort comprised 1587 patients: 92% had RS ≤25 (n = 1455) and 8% had RS >25 (n = 132). With a median follow-up of 74.4 months, the cumulative incidence of local recurrence was low throughout and did not significantly differ between those with RS ≤25 vs >25 (6-year rate 1.9% vs 0.8%; P = .5). Among those who did not undergo RT (n = 350), patients with RS >25 (n = 19) did not have a significantly higher incidence of local recurrence than patients with RS ≤25 (6-year rate 5.6% vs 4.2%; P = .5). CONCLUSIONS: Among patients ≥65 years of age who underwent breast-conserving surgery for early-stage estrogen receptor-positive breast cancer, Oncotype DX RS did not further refine recurrence risk estimates for RT decision-making beyond the findings of landmark RT omission trials. Although the number of patients with Oncotype DX RS >25 who omitted RT was limited in this study, this subgroup did not exhibit a significantly higher risk than their low-molecular-risk counterparts, suggesting that risk score need not necessarily disqualify select patients who seek to forgo adjuvant RT. Prospective analyses with larger sample sizes will further elucidate the role of molecular assays in guiding RT decision-making across risk strata.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Rosenzweig SJ, Boe LA, Wen HY, et al. Molecular Risk Stratification for Decision-Making Among Patients With Breast Cancer Eligible to Omit Radiation Therapy. Int J Radiat Oncol Biol Phys. 2026. PMID: 41895478. doi:10.1016/j.ijrobp.2026.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。